Introduction A leukemia or lymphoma coming back after initial treatment has long been the moment hope turned to dread in Indian families. For years, a relapse meant a narrow, punishing path of salvage chemotherapy with uncertain results. That script is being rewritten. Today, a relapse activates a far more sophisticated treatment ladder inside India. An indigenous CAR-T cell therapy entered its scale phase in 2026, antibody-drug conjugates are producing durable responses in h

Relapsed blood cancer occurs when leukemia, lymphoma, or myeloma returns after initial remission, requiring specialized treatment pathways that differ fundamentally from first-line therapy based on disease biology, prior treatment response, transplant eligibility, and overall fitness. TL;DR Treatment resistance affects 30-40% of blood cancer patients, but salvage chemotherapy, targeted therapy, immunotherapy, stem cell transplant, and CAR-T therapy provide established pathway